Latest Investment News

Challenger Limited has reported a robust first half for the 2025 financial year, with net profit after tax climbing 28.2% and an 11.5% increase in its interim dividend, signaling strong momentum in its financial services operations.

Infratil has increased its investment in CDC Data Centres by acquiring an additional 1.58% stake for approximately A$216 million, reinforcing its commitment to the fast-growing digital infrastructure sector.

Judo Bank has reported a robust half-year performance with a 70% jump in statutory net profit, driven by strong loan growth and improved margins, while reaffirming its FY25 profit guidance.

Judo Capital Holdings Limited reported a robust 54% increase in statutory profit before tax for the half year ended December 2024, driven by strong SME loan growth and prudent cost management, despite a slight dip in net interest margin and statutory profit after tax.

Propell Holdings Limited reported a 75% surge in revenue driven by a rapidly expanding loan book, yet losses more than doubled amid rising impairments. The company is navigating growth challenges while engaging with the ASX on potential delisting.

Maximus Resources Limited has issued a Target's Statement recommending shareholders accept Astral Resources NL's off-market takeover bid, which offers a significant premium and improved liquidity. The offer, valuing Maximus shares at approximately $0.073 each, aims to consolidate gold assets in Western Australia under Astral's larger portfolio.

Far Northern Resources has amended its December 2024 Appendix 5B cash flow report to provide clearer details on investing activities, revealing a net cash outflow and a modest cash balance at quarter-end.

Morphic Ethical Equities Fund Limited reported a robust turnaround with a $2.96 million profit after tax for the half-year ended December 2024, reversing last year’s losses despite no dividends declared.

Health and Plant Protein Group Limited reported a significantly reduced net loss of $43,000 for the half-year ended December 31, 2024, compared to a $748,000 loss in the prior period, despite no operational revenue following the sale of its macadamia division.

Neurizon Therapeutics reported a sharp rise in half-year losses to $7.28 million but marked significant progress with its lead drug NUZ-001 entering a major ALS clinical trial and securing critical regulatory designations.

VanEck Investments Limited has released its indicative dividends calendar for 2025, outlining expected dividend timings for over 50 exchange-traded funds (ETFs). This comprehensive schedule offers investors clarity on dividend announcements, ex-dates, and payment dates across a diverse range of funds.

Simonds Group delivered a resilient $13.6 million EBITDA in 1H FY25 amid a soft residential market and announced a strategic acquisition of Dennis Family Homes to fuel future growth.